High Throughput Screening

高通量筛选核心（HTS）支持基础和转化生物医学研究， 设计、优化和运行高通量分析，为癌症提供潜在的治疗方法。这是 通过将机器人技术、检测系统、化学/生物制品库和数据管理与 在优化技术和成果的专业知识沿着每一步的过程中。HTS提供霍尔顿 综合癌症中心（HCCC）成员，具有可扩展的早期临床前治疗开发， 包括小分子治疗剂、抗体、siRNA、反义寡核苷酸和其他生物制剂 包括源自患者的细胞治疗剂。它还支持高通量筛选研究探索 癌症生物学HTS配备用于在96孔、384孔和1536孔中进行高通量筛选 格式，使用板读数器检测（Perkin-Elmer EnVision），使用吸光度、荧光和 发光，包括先进的FRET和BRET技术。HTS还可以执行高内容筛选 (HCS Perkin-Elmer Operetta共聚焦成像系统）来检测和量化表型变化，即，细胞 细胞分化、细胞迁移、神经突生长和靶向运输，或者通过靶向细胞的荧光强度， 蛋白质表达、转录因子或信号通路分析。

The High Throughput Screening Core (HTS) supports basic and translational biomedical research by designing, optimizing, and running high throughput assays that deliver potential therapeutics for cancer. This is done by integrating robotics, detection systems, chemical /biologics libraries and data management with expertise in optimizing technologies and outcomes along each step in the process. HTS provides Holden Comprehensive Cancer Center (HCCC) members with scalable early, pre-clinical development of therapeutics, including small molecule therapeutics, antibodies, siRNAs, antisense oligonucleotides and other biologics including patient-derived cell therapeutics. It also supports high throughput screening for studies exploring the biology of cancer. The HTS is equipped to perform high-throughput screening in 96-, 384- and 1536- well formats, with plate reader detection (Perkin-Elmer EnVision) using absorbance, fluorescence and luminescence, including advanced FRET and BRET techniques. HTS can also perform high content screening (HCS, Perkin-Elmer Operetta Confocal Imaging System) to detect and quantify phenotypic changes, i.e., cell differentiation, cell migration, neurite outgrowth, and target trafficking or by fluorescence intensities for target protein expression, transcription factor or signaling pathway analysis.